Silvant Capital Management LLC Has $8.82 Million Stock Position in IDEXX Laboratories, Inc. $IDXX

Silvant Capital Management LLC increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 17.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,035 shares of the company’s stock after acquiring an additional 1,918 shares during the quarter. Silvant Capital Management LLC’s holdings in IDEXX Laboratories were worth $8,819,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in IDXX. Virtus Advisers LLC acquired a new position in IDEXX Laboratories in the third quarter valued at approximately $26,000. Park Place Capital Corp acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $29,000. WealthCollab LLC purchased a new stake in IDEXX Laboratories in the 2nd quarter valued at $30,000. Caitong International Asset Management Co. Ltd purchased a new stake in IDEXX Laboratories in the 3rd quarter valued at $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC raised its position in IDEXX Laboratories by 58.8% in the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after buying an additional 20 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of recent analyst reports. UBS Group reduced their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday. Citigroup started coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Finally, Stifel Nicolaus lowered their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Price Performance

IDXX opened at $570.00 on Tuesday. The stock’s 50 day simple moving average is $563.07 and its 200 day simple moving average is $625.43. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. IDEXX Laboratories, Inc. has a 1 year low of $506.91 and a 1 year high of $769.98. The firm has a market cap of $44.96 billion, a price-to-earnings ratio of 41.97, a PEG ratio of 3.07 and a beta of 1.56.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period last year, the company earned $2.91 EPS. IDEXX Laboratories’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.